BD Veritor System for Rapid Detection of SARS-CoV-2 - Sold by kits of 3 (90 tests)

Ideal use for schools, businesses and any organization looking for rapid test results for Covid-19.

BD Veritor™ System for Rapid Detection of SARS-CoV-2

The BD Veritor™ System for Rapid Detection of SARS-CoV-2 is a chromatographic digital immunoassay intended for the direct and qualitative detection of SARS-CoV-2 nucleocapsid antigens in nasal swabs from individuals who are suspected of COVID-19 by their healthcare provider within the first five days of the onset of symptoms. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform moderate, high or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

Test type: Chromatographic digital immunoassay intended for the direct and qualitative detection of SARS-CoV-2 nucleocapsid antigens that is used with the BD Veritor™ Plus Analyzer
Specimen type: Nasal (NS) swab specimens
Turnaround time: 15 minutes
CLIA complexity: Waived, Moderate, and High Complexity
FDA status: EUA granted

Sold by minimum order quantity of 90 tests at a time.
Ships within 48 hours.